Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Amplia Therapeutics Ltd (Amplia Therapeutics) is a clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of focal adhesion kinase (FAK) for the treatment of cancer and fibrotic diseases. The company’s pipeline products include Narmafotinib (AMP945) for pancreatic cancer (gemcitabine/abraxane), pancreatic cancer (folfirinox combination), ovarian cancer, other solid tumours, idiopathic pulmonary fibrosis, other fibrotic diseases and scar reduction; and AMP886 targets solid tumours. Amplia Therapeutics is headquartered in North Melbourne, Victoria, Australia.
Headquarters
Australia
Address
Level 5, 90 William Street, Melbourne, Victoria, 3000
Website
www.ampliatx.com/site/content
Telephone
61 3 91231140
No of Employees
1
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ATX (ASX)
EPS
XYZ
Net Income (2025)
XYZ
-17.3%
(2025 vs 2024)
Market Cap*
$53.1M
Net Profit Margin (2023)
XYZ
81.3%
(2025 vs 2024)
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline |
| Narmafotinib (AMP945): |
| Pancreatic Cancer (Gemcitabine/Abraxane) |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Amplia Therapeutics Ltd | Biotron Ltd | Carina Biotech Pty Ltd | Cartherics Pty Ltd | HaemaLogix Pty Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | Australia | Australia |
| City | Melbourne | Sydney | Mawson Lakes | Notting Hill | Sydney |
| State/Province | Victoria | New South Wales | South Australia | Victoria | New South Wales |
| No. of Employees | 1 | 4 | - | - | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jane Bell | Chairman | Executive Board | 2026 | - |
| Christopher Burns | Managing Director; Chief Executive Officer; Director | Executive Board | 2022 | - |
| Hamish George | Chief Financial Officer | Senior Management | 2026 | - |
| Rhiannon Jones | Chief Operating Officer | Senior Management | - | - |
| Jason Lickliter | Chief Medical Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer